Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) — Financial Flexibility Index
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) has a Financial Flexibility Index of -0.05x as of December 2025. Free cash flow of CN¥-56.73 Million (operating CF CN¥-154.64 Million minus capex CN¥97.92 Million) represents 0% of total liabilities (CN¥1.20 Billion). Check 301096 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Financial Flexibility Index (2019–2025)
Historical Financial Flexibility Index trend for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. across 7 annual periods. For the full cash flow conversion analysis, see 301096 cash flow metrics.
Annual Financial Flexibility Index for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (2019–2025)
Year-by-year free cash flow to debt coverage for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.. Explore 301096 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.05x | CN¥-56.73 Million | CN¥-154.64 Million | CN¥1.20 Billion | ▼ -127.2% |
| 2024 | 0.17x | CN¥199.25 Million | CN¥-195.86 Million | CN¥1.14 Billion | ▼ -77.9% |
| 2023 | 0.79x | CN¥779.05 Million | CN¥90.45 Million | CN¥984.97 Million | ▼ -58.4% |
| 2022 | 1.90x | CN¥850.99 Million | CN¥259.41 Million | CN¥447.45 Million | ▲ +193.2% |
| 2021 | 0.65x | CN¥393.87 Million | CN¥145.42 Million | CN¥607.10 Million | ▼ -33.1% |
| 2020 | 0.97x | CN¥309.48 Million | CN¥54.36 Million | CN¥319.20 Million | ▼ -45.7% |
| 2019 | 1.79x | CN¥178.41 Million | CN¥71.47 Million | CN¥99.89 Million | — |